Tissues identified as containing abnormal PrP and/or infectivity in clinical and subclinical vCJD patients.

<p>Tissues identified as containing abnormal PrP and/or infectivity in clinical and subclinical vCJD patients.</p

Summary of the appendix survey results.

<p>Summary of the appendix survey results.</p

Comparison of incubation periods in wild-type mice.

<p>Incubation period plot comparison of vCJD (transfusion) case versus transmissions in wild-type mice of vCJD (BSE) from three sources. (Data shows mean incubation period±standard error of the mean. Open circles RIII line and open triangles VM line.)</p

Detection of abnormal PrP in the mouse brain.

<p>Immunocytochemical detection of abnormal PrP deposition in hippocampus and thalamus (lateral posterior nucleus) of HuMM transgenic (with additional 40× magnification of florid plaque structure, see box lower left) and VM wild-type mice following inoculation with vCJD (BSE) and vCJD (transfusion) material. (Scale bar 200 µm, anti-PrP antibody 6H4)</p

Vacuolation scoring in the mouse brain.

<p>Lesion profile comparison of vCJD (transfusion) case versus vCJD (BSE) transmissions to identify similarities in vacuolar pathology levels and regional distribution in mouse brains. (mean score ±SEM; dashed line - vCJD (transfusion) case; solid lines – 3x vCJD (BSE) cases for wild-type mice (diamonds – vCJD(BSE) A; squares – vCJD(BSE) B; triangles – vCJD(BSE) C) and published vCJD (BSE) for HuMM transgenic; G1–G9 grey matter scoring regions; W1–W3 white matter scoring regions)</p

Clinical and pathological assessment of wild-type mice.

<p>Wild-type mouse lines RIII and VM, inoculated with vCJD(BSE) and vCJD(transfusion) were assessed clinically and pathologically for signs of TSE and mean incubation periods calculated.</p>a<p>The group of 24 was reduced due to unavailability of some brain material for analysis.</p

PrP^Sc typing by Western blot.

<p>Brain homogenates from HuMM mice inoculated with both vCJD (BSE) and vCJD (transfusion) show similar mobility and glycosylation profile (type 2B) as material from vCJD patients. (T2B: control vCJD material; antibody: 6H4)</p

Representative photomicrographs of a sCJD case with AA (a, c) and a sCJD case with GG (b, d) rs6951643 genotype showing differences in mGluR8 immunostaining of microglial cells in the temporal cortex (a, b) and temporal white matter (c, d).

<p>Bar represents 50 μm for all images.</p

SNPs genotyped in stage two.

<p>sCJD: Sporadic Creutzfeldt-Jakob Disease</p><p>In bold SNPs significant after Bonferroni correction (Replication P-value <0.0023)</p><p>* P-value for allellic diferences adjusted by Country of origin by PCA</p><p>**Chi Squared p-value from comparison between Allele frequencies of independent sCJD cases and stage one controls</p><p>NA: SNP in intergenic region.</p><p>SNPs genotyped in stage two.</p

- rs6951643 pooled genotypes by country.

<p>- rs6951643 pooled genotypes by country.</p